Keeping the diabetic heart healthy

Australian Family Physician

Volumn 34, Issue 6, 2005, Pages 441-445

  Harris, Mark ^a   Wan, Qing ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CASE REPORT; DIABETIC ANGIOPATHY; GENERAL PRACTICE; HEALTH BEHAVIOR; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; MALE; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVENTIVE MEDICINE; REVIEW; RISK FACTOR;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FAMILY PRACTICE; HEALTH BEHAVIOR; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIFE STYLE; MALE; MIDDLE AGED; PREVENTIVE MEDICINE; RISK FACTORS;

EID: 23444455334     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
2. McCarty DJ, Zimmet P, Dalton A, Segal L, Welborn TA. The rise and rise of diabetes in Australia, 1996. A review of statistics, trends and costs. Canberra: Diabetes Australia, 1996.
3. Wu T, Brooks B, Yue D. Macrovascular disease: the sword of Damocles in diabetes. In: Diabetes in the new millennium. Turtle JR, T Kaneko T, Osato S, editors. Sydney: The Endocrinology and Diabetes Research Foundation of the University of Sydney, 1999.
4. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. Diabetes public health resource. Statistics: Diabetes Surveillance, 1999. Available at: www.cdc.gov/diabetes/statistics/survl99/chap5/figure1.htm. Accessed August 2003.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229-34.
6. National Heart, Lung, and Blood Institute. Framingham Heart study. Available at: www.nhlbi.nih.gov/about/framingham/index.html. Accessed 6 October 2003.
7. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple risk factor assessment equations. A statement for health professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
8. Groenveld Y, Petri H, Hermends J, Pringer MP. Relationship between blood glucose level and mortality in type 2 diabetes: a systematic review. Diabet Med 1999;16:2-13.
9. Strattton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321:405-12.
10. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:829-34.
11. Nilsson P, Lundgren H, Soderstom M, Fagerstrom KO, Nilsson-Ehle P. Effects of smoking cessation on insulin and cardiovascular risk factors: a controlled study of 4 months duration. J Intern Med 1996;240:189-94.
12. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2000;1:CD000146.
13. The Royal Australian College of General Practitioners. Smoking, Nutrition, Alcohol and Physical activity: A population health guide to behavioural risk factors for general practices. South Melbourne: RACGP, 2004.
14. Brown LC, Johnson JA, Majumdar SR, Tusyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004;171:1189-92.
15. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
16. UKPDS38. Tight blood pressure control and risk of macrovasculr and microvascular complications in type 2 diabetes. UK Prospective Study Group. BMJ 1998;317:703-13.
17. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004;27:1330-4.
18. Colhoun HM, Betteridge DJ, Durrington PN, et al. On behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo controlled trial. Lancet 2004;364:685-96.
19. Jackson RT. Are the new Lipid Management Guidelines good for Australia's health?. Med J Aust 2001;175:452-3.
20. Harris P, Joyner B, Phillips P, Webster C. The Royal Australian College of General Practitioners. Diabetes management in general practice. 9th ed. Sydney: Beaver Press, 2004.
21. Colwell JA. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2003;26:S87-8.
22. Corns CM. Herbal remedies and clinical biochemistry. Ann Clin Biochem 2003;40:489-507.
23. Diabetes Australia. Draft guidelines for macrovascular disease in people with diabetes. 2004.
24. MiSAD. Milan Study on Atherosclerosis and Diabetes. Prevalence of unrecognised silent myocardial ischemia and its association with atherosclerotic risk factors in non insulin dependent diabetes mellitus. Am J Cardiol 1997;79:134-9.
25. Paillole C, Ruiz J, Juliard JM, Leblanc H, Gourgon R, Passa P. Detection of coronary artery disease in diabetic patients. Diabetologia 1995;38:726-31.
26. Vanzetto G, Halimi S, Hammoud T, et al. Prediction of cardiovascular events in clinically selected high risk nIDDP patients. Prognostic value of exercise stress test and thallium- 201 sing-photon emission computed tomography. Diabetes Care 1999;22:19-26.
27. Bloomgarden ZT. Approaches to cardiovascular disease and its treatment. Diabetes Care 2003;26:3342-8.